conflict
data
concern
sarscov
inhibitori
efficaci
ribavirin
inosin
monophosph
imp
dehydrogenas
inhibitor
studi
done
evalu
efficaci
ribavirin
imp
dehydrogenas
inhibitor
eicar
mizoribin
mycophenol
acid
prevent
viral
replic
lung
balbc
mice
replic
model
sever
acut
respiratori
syndrom
sar
infect
subbarao
ktransfer
neutral
antibodi
prevent
replic
sever
acut
respiratori
syndrom
coronaviru
sarscov
respiratori
tract
mice
j
virol
ribavirin
given
mgkg
h
prior
viru
exposur
given
twice
daili
day
begin
day
found
increas
viru
lung
titer
extend
length
time
viru
could
detect
lung
mice
imp
dehydrogenas
inhibitor
administ
near
maximum
toler
dose
use
dose
regimen
ribavirin
found
slightli
enhanc
viru
replic
lung
addit
ribavirin
treatment
seem
also
promot
product
proinflammatori
cytokin
day
cessat
treatment
although
day
treatment
ribavirin
inhibit
proinflammatori
cytokin
product
infect
mice
significantli
reduc
level
cytokin
monocyt
chemotact
granulocytemacrophag
coloni
stimul
factor
gmcsf
find
suggest
ribavirin
may
actual
contribut
pathogenesi
sarscov
prolong
andor
enhanc
viral
replic
lung
inhibit
viral
replic
lung
infect
mice
ribavirin
treatment
may
provid
continu
sourc
stimul
inflammatori
respons
thought
contribut
pathogenesi
infect
data
support
use
ribavirin
imp
dehydrogenas
inhibitor
treat
sar
infect
human
inosin
monophosph
imp
dehydrogenas
key
enzym
de
novo
synthesi
purin
nucleotid
import
therapeut
target
three
inhibitor
imp
dehydrogenas
reach
market
ribavirin
rebetol
virazol
broadspectrum
antivir
agent
combin
interferonalpha
use
treatment
hepat
c
viru
infect
thought
ribavirin
associ
sar
infect
anoth
inhibitor
eicar
investig
drug
shigeta
fig
imp
dehydrogenas
inhibitor
mention
ribavirin
extens
evalu
sever
acut
respiratori
syndrom
coronaviru
sarscov
cell
cultur
assay
use
actual
treatment
sar
infect
initi
studi
cinatl
et
al
b
suggest
ribavirin
inhibit
sarscov
replic
african
green
monkey
kidney
cell
vero
therapeut
achiev
concentr
subsequ
confirm
sever
laboratori
barnard
et
al
et
al
chen
et
al
tan
et
al
like
ribavirin
phosphoryl
suffici
level
vero
cell
achiev
antivir
effect
howev
other
found
ribavirin
potent
inhibitor
viral
replic
vero
cell
yamamoto
et
al
addit
ribavirin
appar
inhibit
sarscov
replic
rhesu
monkey
kidney
cell
gml
howev
clinic
equival
concentr
dose
would
plasma
level
achiev
human
koren
et
al
morgenstern
et
al
found
ribavirin
efficaci
sarscov
sever
cell
line
includ
embryon
african
green
monkey
kidney
cell
pig
kidney
cell
human
colon
carcinoma
cell
line
clinic
retrospect
studi
shown
ribavirin
facilit
recoveri
patient
infect
sarscov
wang
et
al
random
trial
show
ribavirin
efficaci
zhao
et
al
addit
sar
patient
canada
treat
ribavirin
still
high
copi
number
sarscov
rna
multipl
lobe
lung
time
death
mazzulli
et
al
outcom
patient
treat
hydrocortison
ribavirin
better
plasma
level
sarscov
mrna
increas
second
third
week
ill
compar
receiv
placebo
howev
anoth
studi
five
eight
patient
treat
ribavirin
reduc
viral
load
treatment
three
conflict
data
concern
efficaci
ribavirin
review
cinatl
et
al
studi
done
evalu
ribavirin
well
imp
dehydrogenas
inhibitor
efficaci
prevent
viral
replic
lung
balbc
mous
model
sarscov
african
green
monkey
kidney
cell
vero
human
colon
adenocarcinoma
cell
obtain
american
type
cultur
collect
atcc
manassa
va
usa
embryon
african
green
monkey
kidney
cell
origin
obtain
whitak
bioproduct
walkersvil
md
usa
vero
cell
kindli
provid
center
diseas
control
atlanta
ga
usa
cell
routin
grown
minim
essenti
medium
mem
supplement
heatinactiv
fetal
bovin
serum
fb
hyclon
laboratori
logan
ut
usa
cell
dmem
supplement
fb
antivir
assay
serum
reduc
gentamicin
ad
medium
final
concentr
gml
sever
acut
respiratori
syndrom
coronaviru
strain
urbani
obtain
cdc
routin
passag
vero
cell
experi
involv
infecti
sarscov
carri
laboratori
personnel
wore
complet
bodi
protect
cover
hepafilt
power
air
purifi
respir
ribavirin
obtain
icn
pharmaceut
costa
mesa
ca
ribavirin
monophosph
kindli
provid
dr
zhi
hong
valeant
pharmaceut
intern
costa
mesa
ca
mizoribin
obtain
dr
denni
carson
univers
california
san
diego
eicar
obtain
niaid
antivir
substanc
program
mycophenol
acid
purchas
sigma
st
loui
mo
alferon
n
inject
provid
hemispherx
biopharma
inc
new
brunswick
nj
usa
compound
solubil
minim
essenti
medium
vitro
assay
physiolog
salin
pss
vivo
experi
structur
compound
use
current
studi
shown
fig
modifi
protocol
barnard
et
al
use
vitro
evalu
antivir
efficaci
imp
dehydrogenas
inhibitor
compound
test
vari
concentr
four
log
eight
log
dilut
viru
compound
ad
equal
volum
nearconflu
cell
monolay
tissu
cultur
plate
moi
use
rang
order
produc
viru
cytopath
effect
cell
viru
control
well
within
day
plate
incub
c
cell
viru
control
well
show
complet
viral
cpe
observ
light
microscopi
concentr
drug
assay
viru
inhibit
viral
cpe
triplic
cytotox
duplic
six
well
per
plate
set
asid
uninfect
untreat
cell
control
six
well
per
plate
receiv
viru
repres
control
viru
replic
alferon
hemispherx
biopharma
inc
human
leukocytederiv
interferon
ifn
includ
posit
control
drug
set
compound
test
morpholog
chang
result
cytotox
compound
viru
cytopath
effect
grade
scale
defin
appear
complet
cytotox
cytopath
effect
involv
entir
monolay
observ
light
microscopi
valu
obtain
convert
percent
untreat
uninfect
control
cell
cytotox
dose
viru
inhibitori
dose
repres
put
concentr
monolay
would
show
compound
cytotox
viru
cytopath
effect
respect
estim
regress
analysi
select
index
si
calcul
use
formula
si
activ
cpe
assay
verifi
spectrophotometr
neutral
red
nr
uptak
assay
plate
see
assay
done
cpe
inhibit
test
plate
describ
verifi
inhibitori
activ
cytotox
detect
visual
observ
usual
correl
visual
neutral
red
assay
hand
greater
barnard
et
al
nr
assay
perform
use
modifi
method
cavenaugh
et
al
describ
barnard
et
al
briefli
medium
remov
well
plate
nr
ad
well
plate
plate
incub
h
c
dark
nr
solut
remov
well
rins
remain
dye
extract
use
ethanol
buffer
citrat
buffer
absorb
nm
read
micropl
reader
biotek
el
biotek
instrument
inc
winooski
vt
absorb
valu
express
percent
untreat
control
si
valu
calcul
describ
compound
evalu
sensit
assay
confirm
result
cpe
inhibitionnr
uptak
assay
infecti
viru
yield
well
second
cpe
inhibit
assay
determin
previous
describ
barnard
et
al
cpe
score
describ
plate
frozen
c
thaw
sampl
well
compound
concentr
test
pool
titer
vero
cell
infecti
viru
cpe
assay
previous
describ
barnard
et
al
reduct
viru
yield
calcul
linear
regress
analysi
repres
onelog
inhibit
titer
compar
untreat
viru
control
specif
pathogenfre
balbc
femal
mice
g
rang
vari
experi
obtain
charl
river
laboratori
wilmington
quarantin
h
prior
transfer
facil
adapt
week
use
experi
mice
fed
standard
mous
chow
tap
water
ad
libitum
mous
studi
approv
utah
state
univers
anim
care
use
committe
carri
approv
anim
biosafeti
level
facil
personnel
enter
facil
wore
power
airpurifi
respir
hepa
airmat
saint
paul
mn
infecti
diseas
experi
mice
hous
bonnet
filtertop
cage
place
within
hepafilt
horizont
laminar
flow
ventil
anim
rack
compound
dose
rang
find
experi
done
determin
maximum
toler
concentr
use
dosag
regimen
use
actual
efficaci
studi
compound
thirti
mice
per
group
treat
intraperiton
ip
inject
intranas
administr
appropri
concentr
compound
pss
placebo
h
prior
infect
mice
h
pretreat
mice
sedat
ip
inject
mgkg
ketamin
infect
l
clarifi
viru
lysat
dilut
salin
cell
cultur
viru
passag
ccid
nostril
receiv
approxim
l
anim
treat
twice
daili
bid
appropri
compound
placebo
administ
either
ip
second
dosag
gener
follow
first
h
howev
day
anim
receiv
drug
h
prior
exposur
viru
anoth
dose
immedi
exposur
viru
anoth
dose
h
second
dose
total
three
dose
experi
anim
also
treat
compound
placebo
bid
day
viru
exposur
uninfect
anim
dose
compound
placebo
treat
concentr
drug
placebo
infect
mice
serv
toxic
control
treatment
ceas
day
anim
sacrif
day
postviru
exposur
experi
durat
anim
virusinfect
group
mice
uninfect
group
mice
sacrif
day
postviru
exposur
assay
weight
gain
loss
remain
mice
sacrif
day
assay
weight
gain
loss
well
lung
remov
weigh
score
describ
portion
lung
also
assay
presenc
viru
describ
lung
score
base
surfac
appear
lung
lung
assign
score
mean
lung
look
normal
denot
entir
surfac
area
lung
inflam
show
plum
color
lung
consolid
howev
lung
consolid
seen
model
viral
replic
although
surfac
inflamm
line
lung
note
mani
treat
infect
mice
untreat
mice
mous
lung
homogen
tissu
fragment
allow
settl
vari
dilut
supernat
fluid
assay
triplic
infecti
viru
vero
cell
cpe
assay
titer
ccid
valu
calcul
use
reedmuench
method
reed
muench
differ
mean
lung
weight
viru
titer
analyz
student
ttest
wilcoxon
rank
sum
analysi
use
mean
lung
score
comparison
detect
differ
cytokin
profil
treatment
group
twoway
repeat
analysi
varianc
use
comparison
cytokin
level
two
treatment
individu
cytokin
ttest
use
day
postinfect
lung
sampl
taken
four
mice
treatment
group
lung
sampl
time
point
homogen
volum
adjust
lung
weight
immedi
frozen
store
week
prior
analysi
cytokin
level
supernat
fluid
adjust
total
protein
measur
day
use
quansi
qplex
tm
mous
cytokin
array
platform
chosen
abil
simultan
measur
differ
mous
cytokin
small
sampl
volum
l
cytokin
quantifi
includ
alpha
beta
monocyt
chemotact
interferon
gamma
tumor
necrosi
factor
alpha
macrophag
inflammatori
granulocytemacrophag
coloni
stimul
factor
gmcsf
rant
total
protein
sampl
determin
use
bicinchonin
acid
bca
tm
assay
total
protein
valu
use
adjust
measur
cytokin
level
proport
amount
protein
present
sampl
imp
dehydrogenas
inhibitor
evalu
vitro
none
inhibitori
viru
replic
independ
compound
cytotox
tabl
close
relat
analog
ribavirin
viramidin
also
evalu
found
activ
compound
either
select
inhibitori
inact
concentr
test
toxic
sinc
number
investig
indic
ribavirin
inhibit
sarscov
replic
vitro
even
vero
cell
ribavirin
evalu
vitro
neutral
red
uptak
assay
vero
cell
n
number
independ
experi
vero
cell
n
ribavirin
also
evalu
efficaci
sarscov
infect
cell
cell
viru
yield
reduct
assay
valu
repres
onelog
drop
viru
titer
equal
respect
compar
valu
vero
cell
shown
tabl
evalu
day
exposur
virusinfect
cell
ribavirin
inhibit
viru
yield
high
concentr
n
exposur
similar
result
also
obtain
n
studi
infer
ribavirin
efficaci
sarscov
especi
cell
line
probabl
phosphoryl
tabl
vitro
sarscov
inhibitori
activ
imp
dehydrogenas
inhibitor
alferon
vero
cell
visual
assay
nr
assay
viru
yield
reduct
assay
antivir
activ
form
review
oxford
et
al
hui
wong
morgenstern
et
al
chen
et
al
studi
ribavirin
evalu
efficaci
cell
less
like
phosphoryl
compound
ribavirin
efficaci
sarscov
barnard
et
al
et
al
chen
et
al
tan
et
al
thu
question
remain
ribavirin
truli
inhibit
sarscov
therefor
next
set
studi
done
determin
ribavirin
could
inhibit
sarscov
infect
mous
lung
replic
model
pathogenesi
detect
question
phosphoryl
like
issu
first
set
experi
ribavirin
administ
either
ip
evalu
maximum
toler
dose
balbc
mice
mgkgday
twice
day
begin
h
pretreat
follow
two
treatment
immedi
viru
exposur
h
later
mice
subsequ
treat
bid
day
viru
exposur
sacrif
day
h
last
treatment
mice
treatment
kept
aliv
receiv
treatment
sacrif
day
previou
experi
determin
maximum
lung
viru
titer
obtain
either
day
subsequ
declin
undetect
level
day
data
shown
agreement
studi
current
experi
lung
viru
titer
day
also
level
detect
previou
experi
viru
normal
detect
day
infect
resolv
viru
total
clear
lung
lung
patholog
detect
model
mice
treat
ip
follow
protocol
describ
ribavirintr
anim
infect
uninfect
significantli
p
lost
weight
experi
measur
day
suggest
dose
use
near
threshold
toler
mice
tabl
day
ribavirintr
anim
begun
gain
weight
although
weight
gain
infect
anim
treat
drug
surviv
day
less
anim
treatment
group
surviv
day
ribavirin
treatment
reduc
viral
lung
titer
dose
mgkg
contrari
viru
titer
significantli
higher
day
p
presenc
ribavirin
also
appar
inhibit
clearanc
viru
lung
anim
day
wherea
viru
detect
placebotr
mice
infecti
viru
routin
shown
clear
lung
untreat
infect
anim
day
result
treat
sarscov
infect
mice
use
rout
also
summar
tabl
ribavirintr
mice
lost
weight
experi
measur
day
ribavirintr
mice
shaminfect
group
day
ribavirintr
anim
begun
gain
weight
presenc
drug
although
weight
gain
infect
anim
treat
ribavirin
surviv
day
less
weight
gain
anim
treatment
group
day
ribavirin
treatment
rout
also
significantli
p
reduc
viral
lung
titer
dose
mgkg
viru
titer
higher
placebotr
anim
day
ribavirin
therapi
appear
also
inhibit
clearanc
viru
lung
day
seen
ip
administr
sinc
log
viru
detect
lung
time
wherea
none
detect
placebotr
mice
experiment
design
use
evalu
verifi
unusu
find
describ
use
smaller
mice
g
ribavirin
ip
treatment
reduc
viral
lung
titer
dose
mgkg
tabl
compar
placebotr
infect
mice
titer
significantli
higher
p
previou
experi
viru
titer
higher
day
ribavirin
treatment
inhibit
clearanc
viru
lung
day
similar
result
obtain
administ
ribavirin
although
appear
enhanc
viru
infect
day
tabl
argument
could
made
mgkg
dose
high
frequent
perhap
mice
becam
immunocompromis
led
deleteri
inflammatori
respons
inhibit
protect
immun
respons
allow
viru
overcom
normal
hostrang
specif
permit
normal
mice
clear
infect
without
get
diseas
therefor
experi
done
evalu
efficaci
ribavirin
higher
concentr
administ
singl
dose
evalu
ribavirin
administ
lower
dose
use
dosag
regimen
describ
previou
experi
anim
treat
ribavirin
mgkgday
gain
weight
expect
dose
lower
maximum
toler
dose
tabl
howev
dose
significantli
affect
lung
viru
titer
lead
prolong
infect
happen
mgkg
dosag
regimen
higher
dose
ribavirin
mgkg
administ
one
time
day
viru
infect
inhibit
lung
viru
titer
detect
tabl
viru
detect
lung
mice
sacrif
day
data
shown
lung
homogen
first
experi
ribavirin
administ
mgkgday
bid
day
also
analyz
presenc
cytokin
use
qplex
tm
mous
cytokin
array
system
tabl
includ
analysi
number
proinflammatori
cytokin
includ
detect
signific
level
plasma
sampl
sar
patient
pang
et
al
zhang
et
al
sheng
et
al
result
indic
day
sarscov
infect
induc
significantli
higher
level
cytokin
p
lung
respons
viru
exposur
uninfect
mice
p
concentr
least
threefold
level
detect
uninfect
untreat
mice
infect
mice
level
p
p
p
p
gmcsf
rant
almost
twofold
greater
twofold
found
uninfect
untreat
mice
ribavirin
treatment
infect
mice
day
seem
amelior
induct
cytokin
storm
viru
infect
sinc
level
p
p
p
gmcsf
p
significantli
higher
ribavirintr
anim
compar
virusinfect
anim
ribavirin
treatment
uninfect
mice
seem
perturb
cytokin
respons
compar
placebotr
uninfect
mice
level
cytokin
ribavirintr
infect
mice
somewhat
similar
cytokin
level
uninfect
untreat
mice
although
level
p
p
p
p
p
still
significantli
higher
ribavirintr
infect
mice
contrast
cytokin
profil
found
day
cytokin
profil
somewhat
differ
infect
anim
infect
anim
treat
ribavirin
compar
placebotr
anim
held
day
p
cytokin
level
virusinfect
mice
still
significantli
increas
compar
control
anim
p
p
p
p
p
p
p
gmcsf
p
tabl
cytokin
also
increas
well
includ
rant
day
infect
mice
treat
ribavirin
p
p
p
p
p
p
still
elev
infect
mice
compar
untreat
uninfect
anim
cytokin
level
ribavirintr
infect
anim
compar
virusinfect
anim
level
significantli
lower
ribavirintr
infect
anim
remain
cytokin
level
similar
group
three
group
mice
cytokin
level
p
p
p
p
remain
significantli
higher
virusinfect
virusinfect
treat
anim
day
compar
untreat
uninfect
control
group
anim
day
addit
cytokin
seem
higher
level
virusinfect
virusinfect
treat
anim
day
compar
control
group
anim
day
although
increas
statist
differ
cytokin
seem
reduc
virusinfect
anim
ribavirintr
infect
mice
compar
control
anim
ribavirin
imp
dehydrogenas
inhibitor
inhibit
enzym
ribavirin
one
mechan
wherebi
ribavirin
inhibit
rna
viru
infect
could
conceiv
inhibit
rna
virus
mechan
inhibit
viral
polymeras
activ
triphosph
metabolit
ribavirin
inhibit
viral
cap
guanylyltransferas
activ
viral
cellular
ribavirin
triphosph
induct
mutat
viral
genom
leyssen
et
al
thu
inhibit
viru
replic
could
occur
one
mechan
vitro
data
suggest
perhap
ribavirin
imp
dehydrogenas
inhibitor
modestli
inhibit
sarscov
replic
vitro
tabl
would
imp
dehydrogenas
inhibitor
enhanc
sarscov
replic
mice
would
simpli
inact
demonstr
vitro
therefor
effect
treatment
imp
dehydrogenas
inhibitor
evalu
abil
reduc
lung
viru
titer
use
standard
efficaci
test
protocol
describ
dose
evalu
compound
near
maximum
toler
dose
determin
previou
experi
dose
approxim
lower
maximum
toler
dose
data
shown
result
indic
eicarand
mycophenol
acidtr
mice
lung
viru
titer
increas
increas
dosag
although
increas
lung
viru
titer
quit
significantli
differ
lung
viru
titer
placebotr
infect
mice
tabl
howev
even
though
trend
enhanc
viru
titer
detect
compound
prolong
lung
infect
ribavirin
viru
detect
day
data
shown
although
number
laboratori
shown
ribavirin
efficaci
inhibit
sarscov
vitro
koren
et
al
chen
et
al
chu
et
al
yamamoto
et
al
morgenstern
et
al
saijo
et
al
laboratori
found
ribavirin
inhibit
viru
vitro
huggin
cinatl
et
al
b
barnard
et
al
et
al
tan
et
al
current
data
demon
strate
efficaci
vivo
least
anim
vitro
studi
describ
current
report
demonstr
ribavirin
inact
variou
strain
vero
cell
probabl
due
lack
phosphoryl
activ
triphosph
form
hong
cameron
morgenstern
et
al
cell
line
hpek
presum
capabl
phosphoryl
ribavirin
triphosph
form
ribavirin
found
efficaci
gml
concentr
could
achiev
clinic
morgenstern
et
al
current
studi
ribavirin
evalu
vero
cell
activ
around
gml
also
toxic
averag
gml
studi
ribavirin
also
inhibitori
high
concentr
cell
cell
select
inhibitori
either
cell
line
number
studi
cite
tan
et
al
saijo
et
al
especi
show
efficaci
combin
therapi
interferon
morgenstern
et
al
failur
report
rigor
ie
spectrophotometr
analysi
cytotox
evalu
altern
durat
assay
short
toxic
may
minim
although
studi
ribavirin
still
inhibitori
high
concentr
thu
base
vitro
data
difficult
determin
ribavirin
efficaci
independ
toxic
determin
recommend
treat
sar
infect
number
clinic
studi
ribavirin
et
al
wang
et
al
ribavirin
plu
corticosteroid
peiri
et
al
et
al
initi
use
limit
basi
treat
patient
sar
retrospect
analysi
studi
demonstr
efficaci
ribavirin
mazzulli
et
al
leong
et
al
except
one
studi
treatment
ribavirin
plu
steroid
associ
better
outcom
ribavirin
treatment
alon
studi
find
associ
ribavirin
reduc
viral
load
mazzulli
et
al
addit
two
patient
treat
ribavirin
earli
infect
day
ill
seem
highest
viru
titer
lung
upon
post
mortem
examin
compar
patient
mazzulli
et
al
although
wang
et
al
report
ribavirin
reduc
viral
load
five
eight
patient
addit
appar
lack
efficaci
studi
risk
ribavirininduc
anemia
along
hypoxia
result
increas
risk
death
treat
sar
patient
chiou
et
al
thu
ribavirin
may
use
treat
sar
infect
question
efficaci
known
toxic
review
van
vonderen
et
al
lai
conflict
data
prompt
present
studi
ribavirin
evalu
mous
lung
replic
model
pathogenesi
detect
viru
replic
high
titer
lung
often
snout
maximum
toler
dose
given
first
day
infect
increas
viru
load
lung
fact
appear
increas
viral
load
prolong
infect
lung
find
harmoni
human
studi
cite
mechan
wherebi
ribavirin
may
enhanc
infect
remain
obscur
shown
examin
sera
patient
activ
sar
infect
mazzulli
et
al
pang
et
al
infect
mice
sarscov
also
trigger
larg
increas
inflammatori
chemokin
mice
glass
et
al
larg
increas
proinflammatori
cytokin
sera
patient
recov
sar
infect
also
detect
likewis
shown
larg
increas
proinflammatori
cytokin
lung
balbc
mice
viru
lung
titer
detect
ribavirintr
mice
day
appar
correspond
concomit
increas
level
number
proinflammatori
cytokin
lung
infect
ribavirintr
anim
time
oppos
normal
level
cytokin
detect
infect
control
anim
day
contrast
level
particular
substanti
higher
virusinfect
mice
howev
viru
lung
clear
infect
anim
treat
ribavirin
viru
present
high
level
lung
ribavirintr
infect
anim
observ
may
reflect
find
vitro
along
reduc
viru
titer
detect
cell
cultur
detect
limit
cinatl
et
al
b
scagnolari
et
al
account
lack
detect
viru
anim
lack
interferon
ribavirintr
infect
anim
may
due
lack
suffici
level
control
viru
contrast
day
infect
mice
treat
ribavirin
proinflammatori
cytokin
level
lower
infect
untreat
mice
although
decreas
significantli
differ
cytokin
result
suggest
ribavirin
may
mediat
cytokin
inflammatori
respons
day
howev
viru
load
ribavirintr
infect
mice
significantli
greater
untreat
infect
mice
suggest
return
cytokin
normal
level
enough
inhibit
viral
replic
thu
sar
mous
infect
respons
anim
may
first
character
viral
replic
phase
induc
immun
phase
contribut
pathogenesi
diseas
find
also
suggest
ribavirin
may
actual
contribut
pathogenesi
sarscov
prolong
andor
enhanc
viral
replic
lung
thu
provid
continu
sourc
stimul
inflammatori
respons
thought
contribut
pathogenesi
infect
possibl
also
exist
ribavirin
might
immunomodulatori
properti
advers
affect
clearanc
sarscov
lung
least
mice
exampl
ribavirin
indirect
immunomodulatori
effect
shown
decreas
releas
proinflammatori
cytokin
macrophag
mice
also
shown
suppress
level
balbc
mice
tam
et
al
initi
current
studi
ribavirin
shown
switch
immun
respons
mice
infect
mous
hepat
viru
anoth
coronaviru
respons
ning
et
al
agreement
find
ribavirin
report
promot
tcell
mediat
immun
induct
tam
et
al
none
enhanc
presenc
ribavirin
sar
infect
mice
studi
altern
one
could
argu
inbr
anim
could
potenti
genet
defect
respons
enhanc
viru
infect
presenc
ribavirin
howev
studi
laboratori
indic
total
unrel
compound
promazin
also
enhanc
viral
infect
certain
dose
barnard
et
al
howev
would
interest
evalu
ribavirin
outbr
anim
infect
sarscov
initi
suppress
virusinduc
cytokin
storm
includ
infect
mice
ribavirin
may
upset
balanc
time
respons
thu
ribavirin
treatment
may
alter
cytokin
environ
lung
allow
viral
persist
ie
polar
respons
select
develop
respons
neutral
antibodi
would
normal
abrog
viral
replic
hong
cameron
cytokin
level
mice
day
support
hypothesi
sinc
cytokin
abnorm
high
level
day
final
imp
dehydrogenas
inhibitor
seem
also
enhanc
sarscov
infect
mice
although
lesser
extent
ribavirin
could
suggest
certain
cell
type
essenti
viral
clearanc
type
pneumocyt
alveolar
macrophag
may
function
inhibit
induc
apoptosi
thu
lead
escap
viru
initi
import
first
line
defens
prevent
limit
viral
infect
support
hypothesi
follow
studi
imp
dehydrogenas
inhibitor
shown
induc
apoptosi
number
cell
type
jayaram
et
al
meier
et
al
khanna
et
al
anatol
et
al
ishitsuka
et
al
mycophenol
acid
shown
suppress
product
proinflammatori
cytokin
nitric
oxid
ldh
macrophag
well
inhibit
enzym
imp
dehydrogenas
macrophag
jonsson
carlsten
suppress
metabol
activ
probabl
function
imp
dehydrogenas
inhibitori
properti
mycophenol
acid
sinc
suppress
activ
could
revers
addit
guanosin
addit
mycophenol
mofetil
shown
inhibit
differenti
matur
allostimulatori
function
human
monocytederiv
dendrit
cell
colic
et
al
ribavirin
also
shown
inhibit
macrophag
product
proinflammatori
cytokin
cytokin
preserv
cytokin
induct
ning
et
al
thu
right
condit
imp
dehydrogenas
inhibitor
may
actual
promot
viral
infect
suppress
function
inhibit
cell
type
necessari
normal
clearanc
viru
result
strongli
suggest
use
ribavirin
therapi
treat
sar
infect
reconsid
anim
studi
clarifi
effect
ribavirin
cytokin
chemokin
profil
infect
ribavirin
demonstr
signific
effect
reduc
viral
replic
vivo
